EGFR and cancer: Moreover, the PI3K-Akt signaling pathway (45) downstream of EGFR, activated in drug-resistant cancer cells with loss of EGFR driver gene mutation, was highly expressed in post-treatment tumors (Supplementary Figure S4C).